223 related articles for article (PubMed ID: 17252594)
21. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma.
Kosunen A; Pirinen R; Ropponen K; Pukkila M; Kellokoski J; Virtaniemi J; Sironen R; Juhola M; Kumpulainen E; Johansson R; Nuutinen J; Kosma VM
Oral Oncol; 2007 Jan; 43(1):51-9. PubMed ID: 16798062
[TBL] [Abstract][Full Text] [Related]
22. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis.
Hrabec E; Strek M; Nowak D; Greger J; Suwalski M; Hrabec Z
J Cancer Res Clin Oncol; 2002 Apr; 128(4):197-204. PubMed ID: 11935310
[TBL] [Abstract][Full Text] [Related]
23. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer.
Liu SC; Yang SF; Yeh KT; Yeh CM; Chiou HL; Lee CY; Chou MC; Hsieh YS
Clin Chim Acta; 2006 Sep; 371(1-2):92-6. PubMed ID: 16581051
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer.
Jordan RC; Macabeo-Ong M; Shiboski CH; Dekker N; Ginzinger DG; Wong DT; Schmidt BL
Clin Cancer Res; 2004 Oct; 10(19):6460-5. PubMed ID: 15475433
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
26. Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials.
Erdem NF; Carlson ER; Gerard DA; Ichiki AT
J Oral Maxillofac Surg; 2007 Sep; 65(9):1725-33. PubMed ID: 17719389
[TBL] [Abstract][Full Text] [Related]
27. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons.
Wu MH; Hong TM; Cheng HW; Pan SH; Liang YR; Hong HC; Chiang WF; Wong TY; Shieh DB; Shiau AL; Jin YT; Chen YL
Mol Cancer Res; 2009 Mar; 7(3):311-8. PubMed ID: 19276182
[TBL] [Abstract][Full Text] [Related]
28. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis.
Kawamata H; Uchida D; Hamano H; Kimura-Yanagawa T; Nakashiro KI; Hino S; Omotehara F; Yoshida H; Sato M
Int J Oncol; 1998 Oct; 13(4):699-704. PubMed ID: 9735398
[TBL] [Abstract][Full Text] [Related]
29. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
[TBL] [Abstract][Full Text] [Related]
30. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
31. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
32. Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors.
Nakaichi M; Yunuki T; Okuda M; Une S; Taura Y
Res Vet Sci; 2007 Apr; 82(2):271-9. PubMed ID: 17011604
[TBL] [Abstract][Full Text] [Related]
33. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
34. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma.
Wiegand S; Dünne AA; Müller HH; Mandic R; Barth P; Davis RK; Werner JA
Cancer; 2005 Jul; 104(1):94-100. PubMed ID: 15912516
[TBL] [Abstract][Full Text] [Related]
35. ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression.
Iwai S; Amekawa S; Yomogida K; Sumi T; Nakazawa M; Yura Y; Nishimune Y; Nozaki M
Oral Dis; 2008 Mar; 14(2):144-9. PubMed ID: 18302674
[TBL] [Abstract][Full Text] [Related]
36. Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis.
Nomura H; Uzawa K; Yamano Y; Fushimi K; Ishigami T; Kouzu Y; Koike H; Siiba M; Bukawa H; Yokoe H; Kubosawa H; Tanzawa H
Hum Pathol; 2009 Jan; 40(1):83-91. PubMed ID: 18789482
[TBL] [Abstract][Full Text] [Related]
37. [Matrix metalloproteinases map of lymphogenous metastasis of hepatocarcinoma cell in mice].
Cui XN; Hou L; Liu JW; Ling MY
Ai Zheng; 2002 Nov; 21(11):1192-6. PubMed ID: 12526214
[TBL] [Abstract][Full Text] [Related]
38. [Correlations of serous levels of matrix metalloproteinases (MMP-2 and MMP-9) to invasion and metastasis of papillary thyroid carcinoma].
Yu HZ; Li ZP; Li SG; Wu CM
Ai Zheng; 2005 Jun; 24(6):740-2. PubMed ID: 15946492
[TBL] [Abstract][Full Text] [Related]
39. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
40. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer.
Bogusiewicz M; Stryjecka-Zimmer M; Szymanski M; Rechberger T; Golabek W
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):132-6. PubMed ID: 12574771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
